Killing Dynamics of Carbapenems against Pseudomonas aeruginosa Harboring Varied Determinants of Carbapenem Resistance by 정석훈
73
This is an Open Access article 
distributed under the terms of 
the Creative Commons Attribution Non-Commercial 
License (http: //creativecommons.org/licenses/by-
nc/4.0/) which permits unrestricted non-commercial 
use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
© 2020 Korean Society of Clinical Microbiology.
Annals of Clinical Microbiology 2020 June Vol.23(2)
Accepted: November 15, 2019
Revised: November 15, 2019
Received: July 24, 2019
https://doi.org/10.5145/ACM.2020.23.2.4










다양한 내성 기전의 녹농균에 대한 카바페넴의 
살균 동역학
Viga Rolly1*, 이은정2*, 윤은정3, 정석훈3
1연세대학교 보건대학원 글로벌 보건안보학과, 2상지대학교 임상병리학과, 3연세대학교 의과대학 진단검사의학교실 
및 세균내성연구소
Killing Dynamics of Carbapenems against 
Pseudomonas aeruginosa Harboring Varied 
Determinants of Carbapenem Resistance
Viga Rolly1*, Eun Jung Lee2*, Eun-Jeong Yoon3, Seok Hoon Jeong3
1Global Health Security, Graduate School of Public Health, Yonsei University, Seoul, 2Sangji University 
College of Science, Wonju, 3Department of Laboratory Medicine and Research Institute of Bacterial 
Resistance, Yonsei University, College of Medicine, Seoul, Korea
* These authors contributed equally to this work.
ABSTRACT
Background: Ideal dose of the antimicrobials should be decided by considering their killing 
dynamics since sufficient elimination of the causative microorganisms is critical for proper 
antimicrobial treatment. In this study, the bactericidal activities of carbapenems by resistance 
mechanisms were assessed for carbapenem-resistant Pseudomonas aeruginosa.
Methods: Minimal inhibition concentrations (MICs) of carbapenems were determined by 
broth dilution method and the resistance mechanisms were identified by PCR and DNA 
sequencing. The expression levels of efflux pumps were determined by reverse transcriptase 
real-time PCR. Time-kill curves were plotted by time-course numeration of the viable cells 
grown under imipenem and meropenem at 1× and 4×MICs, respectively.
Results: One P. aeruginosa strain was susceptible, whereas three were resistant to 
carbapenems by defective OprD, efflux pump overproduction, and/or IMP-6 production. 
The susceptible strain had imipenem and meropenem MICs of 2 and 1 mg/L, respectively. 
The MICs were elevated by eight-fold by defective OprD, 16- and 32-fold by the pump 
overproduction, and four- and >64-fold by the combination of two determinants and the 
IMP-6 carbapenemase. While both the carbapenems showed time-dependent bactericidal 
activity to the susceptible isolate, either of the carbapenem-resistant determinants, such 
as decreased membrane permeability, carbapenemase production, or the defective OprD, 
presented concentration-dependent bacteriostatic activity.
Conclusion: Different killing dynamics of the carbapenems were observed depending on 
the resistance determinants, and the results would guide a proper treatment strategy for the 
patients using these drugs.
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INTRODUCTION
Pseudomonas aeruginosa is an opportunistic pathogen causative for healthcare-associated infections [1]. 
Carbapenems are a major treatment option for infections caused by drug-resistant P. aeruginosa. However, 
increasing proportion of the carbapenem resistance in the P. aeruginosa clinical strains is of concern [2]. The 
resistance mechanism of the drug includes i) membrane impermeability either by deficiency of the outer-
membrane porin OprD or by overexpression of the resistance-nodulation cell division (RND) efflux pumps 
such as MexAB-OprM and MexXY-OprM [3] and ii) acquisition of the carbapenemase gene, such as a 
class A Guiana extended-spectrum beta-lactamase (GES) of some subtypes and class B imipenemase (IMP) 
and Verona integron-encoded metallo-beta-lactamase (MBLs) (VIM) [4]. The level of resistance depends 
on the resistance determinants. The carbapenemase confers mid- to high-level resistance, while membrane 
impermeability leads only reduced susceptibility. The clinical strains often carry two or more resistance 
determinants and the interplay of multiple determinants has been demonstrated to confer higher level 
resistance to carbapenems [5].
Since elimination of the infection-causative microorganisms is critical to succeed the treatment, 
antimicrobial doses should be decided in consideration of the killing dynamics. Consequently, characterizing 
the killing effect of antimicrobials, including its bacteriostatic and bactericidal activity, is principal to optimize 
antimicrobial pharmacodynamics. While many efforts have been made to know the killing dynamics of 
drugs against drug-susceptible bacteria [6], that against the drug-resistant bacteria harboring single or multiple 
resistance determinants to carbapenems has been insufficiently established and the altered killing dynamics 
by common resistance determinant is needed. And in this study, we evaluated the killing dynamics of 
carbapenems against P. aeruginosa strains having varied common mechanisms of carbapenem resistance.
MATERIALS AND METHODS
Bacterial strains and Antimicrobial susceptibility testing
Four P. aeruginosa blood isolates from three general hospitals in South Korea between 2016 and 2017 
were used. Bacterial species were identified by matrix-assisted laser desorption ionization–time of flight 
mass spectrometry using a Bruker MALDI Biotyper® instrument (Bruker, Billerica, MA, USA) under the 
criteria of the log score above 2.0. Minimal inhibitory concentrations (MICs) of imipenem (Sigma-Aldrich, 
St. Louis, MO, USA) and meropenem (Sigma-Aldrich) were determined by broth microdilution methods 
using Mueller-Hinton (MH) broth and both Escherihia coli ATCC 25922 and P. aeruginosa ATCC 27853 
were used for quality control [7].
DNA manipulation and polymerase chain reaction (PCR)
Total DNA was extracted using MG Genomic DNA Purification kit (MG MED Inc., Seoul, Korea). PCR 
and following Sanger sequencing was carried out for known acquired carbapenemases, such as blaIMP, blaVIM, 
blaKPC, blaNDM, and blaGES [8], and the oprD gene [9].
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Determination of the efflux pump overexpression
Total RNA was extracted from exponentially growing bacterial cells by using RNeasy® plus mini (Qiagen, 
Hilden, Gemany). Levels of mRNA for the three RND efflux pumps, and the house-keeping rpoB gene 
was quantified by LightCycler® 480 instrument II (Roche Diagnostics, Rotkreuz, Switzerland) using the 
LightCycler® RNA amplification kit with SYBR green I (Roche Diagnostics) using gene-specific primer 
pairs 5ʹ-CAAGGGCGTCGGTGACTTCCA-3ʹ and 5ʹ-ACCTGGGAACCGTCGGGATTGA-3ʹ for 
mexB, 5ʹ-GGACCACGCCGAAACCGAACG-3ʹ and 5ʹ-CGCCGCAACTGACCCGCTACA-3ʹ for 
mexY, 5 -́GGACGGCTCGCTGGTCCGGCT-3  ́and 5 -́CGACGAAGCGCGAGGTGTCGT-3  ́for mexD, 
5ʹ-CTTGGTACGACCGTTCACGT-3  ́and 5ʹ-GCTGAAACTGAACCACCTGG-3  ́for rpoB with the 
following cycles: predenaturtation at 95°C for 30 s, followed by 45 cycles at 95°C for 5 s, 58°C for 10 s, and 
72°C for 20 s. The transcriptome levels of each pump were normalized to that of rpoB, and relative levels 
were calculated by dividing those of the P. aeruginosa A1701DS. Each experiment was performed in duplicate 
twice independently.
Time–kill assay
Each strain was grown in MH broth till mid-exponential phase and were diluted to have 106 colony 
forming units (CFU)/mL. Drugs were then added at 1× (2 mg/L imipenem and 1 mg/L meropenem) and 4
× MICs (8 mg/L imipenem and 4 mg/L meropenem). CFUs were numerated by plating every two hours and 
plotted. The killing kinetics were determined twice independently, and verified the results being reproducible. 
Bactericidal activity was defined as a ≥3.0 log CFU/mL decrease in bacterial count at any time point during 
the 24-hour exposure of the drug.
RESULTS
Carbapenem susceptibility and the relevant mechanism
The four P. aeruginosa strains studied included one carbapenem-susceptible and three carbapenem-resistant 
strains (Table 1). P. aeruginosa A1701DS was susceptible to both carbapenems and MICs of imipenem and 
meropenem were 2 mg/L and 1 mg/L, respectively. The three carbapenem-resistant strains had varied MICs 
of both drugs. P. aeruginosa B1707∆oprD strain had the imipenem MIC of 16 mg/L and the meropenem MIC 
of 8 mg/L. P. aeruginosa F1709pump↑ had both carbapenem MICs of 32 mg/L, and B1605∆oprD/ pump↑/IMP had 
MICs of 8 mg/L and >64 mg/L of imipenem and meropenem, respectively.
Except the carbapenem-susceptible P. aeruginosa A1701DS, the three P. aeruginosa strains had single or 
multiple mechanisms of carbapenem resistance (Table 1). Defective OprD was identified in P. aeruginosa 
B1707∆oprD and B1605∆oprD/ pump↑/IMP strains. Overexpression of the RND pump was observed in two P. 
aeruginosa strains. The MexAB-OprM RND efflux pump of the three tested RND efflux systems was 
1.40- fold overexpressed in P. aeruginosa F1709pump↑. For the P. aeruginosa B1605∆oprD/ pump↑/IMP, 1.64-
fold overexpression of the MexAB-OprM, 3.37-fold overexpression of the MexXY-OprM, and 2.84-fold 
overexpression of the MexCD-OprJ RND efflux system were observed. The P. aeruginosa B1605∆oprD/ pump↑/
IMP harbored the blaIMP-6 gene for MBL.
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Time-kill kinetics of carbapenems on P. aeruginosa carrying varied 
mechanisms of resistance
Fig. 1 showed the killing dynamics of imipenem and meropenem. Both carbapenems demonstrated rapid 
time-dependent killing kinetics against the drug-susceptible P. aeruginosa A1701DS strain at 1×and 4×MICs. 
By the 24-hour incubation at 1×MIC of imipenem, regrowth of the strain was observed. The meropenem 
presented clear concentration-dependent killing dynamics against P. aeruginosa B1707∆oprD. Within 8 hours, 
elimination of 3.0 log CFU/mL were observed. The imipenem presented concentration-dependent killing 
kinetics against P. aeruginosa B1707∆oprD, however, it only exhibted 1.0 log CFU/mL elimination by 2 hours. 
Finally, both the RND pump-overproducing strains, the F1709pump↑ and the B1605∆oprD/ pump↑/IMP were not killed 
by meropenem at all, while concentration-dependent killing dynamics by imipenem were observed.
DISCUSSION
Adequate antimicrobial therapy is critical for the outcome of the patients with infectious diseases and the 
in vitro kinetics of bacterial killing is one of the key factors for guiding the proper antimicrobial choice as 
dead bugs don�t mutate [10]. Even though the definitions of �bacteriostatic� and �bactericidal� are clear, no 
antimicrobial agents could be definitively categorized into the two, since the killing kinetics of the drug is 
dependent on the targeting bacteria, inoculum size, and so on [11].
The carbapenems are one of the last-line drugs to treat P. aeruginosa infections. Since the drugs are used 
empirically for the critically ill patients, resistance to the drug is critical for the patient�s outcome [12]. The 
three resistance determinants, i.e. OprD deficiency, overproduction of the RND efflux pump, and MBL 
production, are common mechanisms of resistance to carbapenems globally in P. aeruginosa [13]. In addition, 
the IMP-6-producing P. aeruginosa used in the study is disseminated in South Korea since the end of the 
2000s [9,14]. Thus, bacterial killing effects of carbapenems against the P. aeruginosa carrying the resistance 
determinants was needed to be evaluated.
Table 1. Carbapenem susceptibility and relative level of efflux pump gene expression in P. aeroginosa 
strains
P. aeruginosa
MIC (mg/L) of* Relative level of expression to A1701DS
†
Imipenem Meropenem MexAB-OprM MexXY-OprM MexCD-OprJ
A1701DS 2 1 1.0 1.0 1.0
B1707∆oprD 16  8 0.6  0.3 -
‡
F1709pump↑ 32  32 1.4 0.6 0.7
B1605∆oprD/ pump↑IMP 8  >64 1.6 3.4 2.8
*MICs were determined by broth dilution method. Imipenem and meropenem MICs in quality 
control strain P. aeruginosa ATCC 27853 were 4 and 0.5 mg/L, respectively.
†The relative level of pump expression was determined for the RND pump genes, mexB for 
MexAB-OprM, mexY for MexXY-OprM, and mexD for MexCD-OprJ.
‡No mexD gene was identified by PCR.
Abbreviation: MICs, minimal inhibitory concentrations.
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Fig. 1. Time–kill curves of imipenem and meropenem against P. aeruginosa (A) A1701DS, (B) B1707∆oprD, (C) F1709 pump↑, (D) 
B1605∆oprD/ pump↑/IMP strains. Number of bacterial colony forming units are presented to the detection limit (10
2 CFU/mL). Black circle 
and black solid line, no antibiotics treated; gray circle and gray solid line, 1×MIC; and open circle and black broken line, 4×MIC.
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Carbapenems showed a time-dependent bactericidal activity to the susceptible isolate as the most beta-
lactams do. Certain regrowth of the bacteria by 24 hours under the 1×MIC imipenem was likely due to 
the collaborative effect of the poor chemical stability of the drug and the intrinsic cephalosporinase leaky in 
P. aeruginosa, which has a very weak carbapenemase-hydrolyzing activity. While deficiency of the OprD 
elevated the MICs of both carbapenems equally by eight folds, clear concentration-dependent killing kinetics 
of the meropenem was observed against the OprD-defective strain by eliminating 3.0 log CFU/mL in 
eight hours at the 4×MIC. Conceivably, the difference was led by imipenem preference of the porin [15]. 
Meropenem MICs were much more elevated by overproduction of the efflux pump, especially that of the 
MexAB-OprM having preference to meropenem [3,16]. The IMP-6 carbapenemase production resulted 
in additional elevation of the meropenem MIC on top of the RND efflux pump overexpression. Imipenem 
susceptibility was not affected by the IMP-6 making a good correlation with the previous report of the 
enzyme hydrolyzing efficiently the meropenem rather than the imipenem [17]. Further attention is needed to 
the carbapenemase producers, since they often harbor class 1 integron including multiple gene cassettes of 
drug resistance [18] resulting in multidrug-resistance elevating mortality of the victimized patients [19].
Notably, the mechanisms of carbapenem resistance threat the patients not only by limiting the drug choices 
for treatment, but also by putting the patients at risk through its alternative role as a virulence factor, and 
the point highlights the importance to identify the actual mechanism of carbapenem resistance. Recently, 
the OprD deficiency in P. aeruginosa was recognized as a risk factor for the patients with P. aeruginosa 
bloodstream infections by augmenting the 6-week mortality from 17.2% to 33.3% [20]. The RND efflux 
pump is also known to be associated with the bacterial virulence mostly by involving in the biofilm formation 
and quorum sensing [21,22].
This study has an obvious imperfection of limited number of strains. However, the killing kinetics of 
carbapenems would help to better optimize the antimicrobial pharmacodynamics against P. aeruginosa 
clinical strains harboring common mechanisms of carbapenem resistance. To conclude, both the time-
dependent killing kinetics and bactericidal activity of carbapenems were affected by any of the common 
resistance determinants. The defective OprD diminished the killing activity of imipenem rather than that of 
meropenem, while the RND pump overproduction and the meropenemase MBL IMP-6 weaken the activity 
of meropenem than that of imipenem.
요약
배경: 최적의 항균제 투여에 의한 감염 원인균의 효율적 제균은 세균 감염증 치료에 필수적이며, 
이상적인 항균제 투여량은 약물의 살균 동역학을 바탕으로 결정된다. 본 연구에서는 다양한 내성 
기전의 카바페넴 내성 녹농균에 대한 카바페넴의 살균력을 평가하였다.
방법: 환자의 혈액검체에서 분리된 녹농균을 사용하였다. 카바페넴의 최소 억제농도는 미량 액
체배지 희석법으로 결정하였고, 카바페넴 내성 결정요소는 연쇄중합효소반응 및 염기서열 분석
을 통하여 규명하였다. 항생제 유출펌프의 발현 정도는 실시간 역전사 연쇄중합효소반응으로 측
정하였다. 최소 억제농도의 1배 또는 4배 농도의 이미페넴이나 메로페넴 용액에서 녹농균 균주를 
배양하며 매 시간 집락 수를 측정하여 살균 동역학 커브를 작성하였다.
Killing Dynamics of Carbapenems
Annals of Clinical Microbiology 2020 June Vol.23(2) 79
결과: 실험 대상 균주 4주 중 1주는 카바페넴에 감수성이었으며, 3주는 OprD 결손, 항생제 유출펌
프 과생성 및 IMP-6 효소 생성으로 인해 카바페넴 내성을 획득한 균주였다. 감수성 균주의 이미
페넴 최소 억제농도는 2 mg/L, 메로페넴은 1 mg/L 이었으며, 이들 두개 항생제의 최소 억제농도는 
OprD 결손에 의해 각 8배, 항생제 유출펌프 과발현에 의해 16 및 32배, OprD 결손, 항생제 유출펌
프 과발현, IMP-6 생성의 3가지 내성결정요소에 의해 각 4배와 >64배 상승하였다. 카바페넴 감수
성 균주는 이미페넴과 메로페넴 모두에 대해 시간 의존성 살균효과를 나타낸 반면, 카바페넴 내성 
균주는 농도 의존성 정균효과를 보였다. 이미페넴은 OprD 결손 또는 IMP-6 생성 균주, 메로페넴
은 OprD 결손균주에 대하여 농도 의존성 정균효과가 있었다.
결론: 카바페넴은 녹농균의 내성 기전에 따라 상이한 살균 동역학을 보였다. 본 연구의 결과는 카
바페넴 내성 녹농균 감염증의 항균제 치료 가이드라인 확립에 도움을 줄 것으로 생각한다.
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